OvaScience does Not Expect to Meet 2015 Goal of 1,000 AUGMENTSM Treatment Cycles

Loading...
Loading...
OvaScienceSM
OVAS
today announced that the Company does not expect to meet the 2015 goal of 1,000 AUGMENTSM treatment cycles. The AUGMENT treatment patient experience has been positive and OvaScience has built strong technical operations, quality and manufacturing; however, the Company is continuing to enhance its commercial operations and infrastructure to optimize for commercial success. In addition, evolving market dynamics in the fertility space, including recent merger and acquisition activities at the key commercial IVF clinics where the AUGMENT treatment is offered, have hindered the Company's ability to drive major volume that was anticipated in the fourth quarter.
See full press release
Market News and Data brought to you by Benzinga APIs
Posted In: NewsGuidancePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...